title: Posterior reversible encephalopathy syndrome (PRES) during induction chemotherapy for acute myeloblastic leukemia (AML).
authors.forename: Giorgia
authors.initials: G
authors.lastname: Battipaglia
authors.forename: Simona
authors.initials: S
authors.lastname: Avilia
authors.forename: Emanuela
authors.initials: E
authors.lastname: Morelli
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Caranci
authors.forename: Fabiana
authors.initials: F
authors.lastname: Perna
authors.forename: Andrea
authors.initials: A
authors.lastname: Camera
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D060828:Induction Chemotherapy / Q000009:adverse effects*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D055815:Young Adult
chemical_list: D003561:Cytarabine; D005047:Etoposide; D003630:Daunorubicin